Cargando…

Cannabidiol (CBD) and Δ(9)-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial

INTRODUCTION: Insomnia is a highly prevalent and costly condition that is associated with increased health risks and healthcare utilisation. Anecdotally, cannabis use is frequently reported by consumers to promote sleep. However, there is limited research on the effects of cannabis on sleep and dayt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suraev, Anastasia, Grunstein, Ronald R, Marshall, Nathaniel S, D'Rozario, Angela L, Gordon, Christopher J, Bartlett, Delwyn J, Wong, Keith, Yee, Brendon J, Vandrey, Ryan, Irwin, Chris, Arnold, Jonathon C, McGregor, Iain S, Hoyos, Camilla M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Pharmacology and Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239553/ https://www.ncbi.nlm.nih.gov/pubmed/32430450 http://dx.doi.org/10.1136/bmjopen-2019-034421

Ejemplares similares

O006 Acute effects of combined cannabidiol (CBD) and ∆9-tetrahydrocannabinol (THC) in insomnia disorder: A randomised, placebo-controlled trial using high-density EEG
por: Suraev, A, et al.
Publicado: (2022)

Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition
por: Arkell, Thomas R., et al.
Publicado: (2019)

A protocol for the delivery of cannabidiol (CBD) and combined CBD and ∆(9)-tetrahydrocannabinol (THC) by vaporisation
por: Solowij, Nadia, et al.
Publicado: (2014)

Are adverse effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?
por: Lachenmeier, Dirk W., et al.
Publicado: (2023)

Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis
por: Hutten, Nadia R. P. W., et al.
Publicado: (2022)

Conversion of Cannabidiol (CBD) into Psychotropic Cannabinoids Including Tetrahydrocannabinol (THC): A Controversy in the Scientific Literature
por: Golombek, Patricia, et al.
Publicado: (2020)

The Effect of Orally Administered Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) on Obesity Parameters in Mice
por: Eitan, Adi, et al.
Publicado: (2023)

Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD)
por: Meyer, Thomas, et al.
Publicado: (2019)

Proteome-Wide Profiling Using Sample Multiplexing of a Human Cell Line Treated with Cannabidiol (CBD) and Tetrahydrocannabinol (THC)
por: Abyadeh, Morteza, et al.
Publicado: (2023)

Motor neuron development in zebrafish is altered by brief (5-hr) exposures to THC (∆(9)-tetrahydrocannabinol) or CBD (cannabidiol) during gastrulation
por: Ahmed, Kazi T., et al.
Publicado: (2018)

Orally administered cannabidiol does not produce false‐positive tests for Δ(9)‐tetrahydrocannabinol on the Securetec DrugWipe® 5S or Dräger DrugTest® 5000
por: McCartney, Danielle, et al.
Publicado: (2021)

Differences in Inhibitory Control and Resting Brain Metabolism between Older Chronic Users of Tetrahydrocannabinol (THC) or Cannabidiol (CBD)—A Pilot Study
por: Rudroff, Thorsten, et al.
Publicado: (2022)

Comment on Lachenmeier et al (2020) “Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?”: disputation on various points in the publication
por: Kruse, Daniel, et al.
Publicado: (2020)

A Critical Review of the Role of the Cannabinoid Compounds Δ(9)-Tetrahydrocannabinol (Δ(9)-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment
por: Jones, Éamon, et al.
Publicado: (2020)

Study of Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) extraction FROM dried oral fluid spots (DOFS) and LC–MS/MS detection
por: Gorziza, Roberta, et al.
Publicado: (2021)

Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder (‘CUPID’ study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial
por: Lavender, Isobel, et al.
Publicado: (2023)

Pilot clinical and pharmacokinetic study of Δ(9)-Tetrahydrocannabinol (THC)/Cannabidiol (CBD) nanoparticle oro-buccal spray in patients with advanced cancer experiencing uncontrolled pain
por: Clarke, Stephen, et al.
Publicado: (2022)

Evaluation of the preclinical analgesic efficacy of naturally derived, orally administered oil forms of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and their 1:1 combination
por: Linher-Melville, Katja, et al.
Publicado: (2020)

Efficacy of Δ(9) -Tetrahydrocannabinol (THC) Alone or in Combination With a 1:1 Ratio of Cannabidiol (CBD) in Reversing the Spatial Learning Deficits in Old Mice
por: Nidadavolu, Prakash, et al.
Publicado: (2021)

Biomechanical Effects of Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD), the Major Constituents of Cannabis, in a Sprague Dawley Rat Achilles Tendon Surgical Repair Model
por: Stauch, Chris M., et al.
Publicado: (2020)

Differential Effects of D9 Tetrahydrocannabinol (THC)- and Cannabidiol (CBD)-Based Cannabinoid Treatments on Macrophage Immune Function In Vitro and on Gastrointestinal Inflammation in a Murine Model
por: Yekhtin, Zhanna, et al.
Publicado: (2022)

Effects of cannabidiol on simulated driving and cognitive performance: A dose-ranging randomised controlled trial
por: McCartney, Danielle, et al.
Publicado: (2022)

Cannabidiol (CBD) and Insomnia : Literature review
por: Gutierrez Higueras, T., et al.
Publicado: (2022)

Biomechanical Effects of Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD), the Major Constituents of Cannabis, on Tendon to Tendon Healing in a Sprague Dawley Rat Achilles Tendon Surgical Repair Model
por: Stauch, Chris, et al.
Publicado: (2020)

Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial
por: Zamarripa, C. Austin, et al.
Publicado: (2023)

P018 The effects of zopiclone on sleep spindles in obstructive sleep apnea: A randomized placebo-controlled trial
por: Carter, S, et al.
Publicado: (2021)

Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios
por: Englund, Amir, et al.
Publicado: (2022)

Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
por: Hardy, Janet, et al.
Publicado: (2020)

P066 A randomised, double-blind, placebo-controlled, single-dose, crossover, pilot study investigating the effects of cannabinol (CBN) 30 mg and 300 mg on sleep architecture and next-day function in insomnia disorder
por: Lavender, I, et al.
Publicado: (2022)

CBD, a precursor of THC in e-cigarettes
por: Czégény, Zsuzsanna, et al.
Publicado: (2021)

Detection of Δ(9) THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two point‐of‐collection testing devices
por: Arkell, Thomas R., et al.
Publicado: (2019)

Long-Term Consequences of Adolescent Exposure to THC-Rich/CBD-Poor and CBD-Rich/THC-Poor Combinations: A Comparison with Pure THC Treatment in Female Rats
por: Gabaglio, Marina, et al.
Publicado: (2021)

Oral Tetrahydrocannabinol (THC):Cannabinoid (CBD) Cannabis Extract Adjuvant for Reducing Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial
por: Sukpiriyagul, Apichaya, et al.
Publicado: (2023)

Cannabidiol (CBD) in Cancer Management
por: O’Brien, Kylie
Publicado: (2022)

Insomnia subtypes characterised by objective sleep duration and NREM spectral power and the effect of acute sleep restriction: an exploratory analysis
por: Kao, Chien-Hui, et al.
Publicado: (2021)

Impaired Neurobehavioural Performance in Untreated Obstructive Sleep Apnea Patients Using a Novel Standardised Test Battery
por: D'Rozario, Angela L., et al.
Publicado: (2018)

The Impact of THC and CBD in Schizophrenia: A Systematic Review
por: Ahmed, Saeed, et al.
Publicado: (2021)

The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence
por: Arnold, Jonathon C., et al.
Publicado: (2022)

Adolescent Sleep Patterns and Night-Time Technology Use: Results of the Australian Broadcasting Corporation's Big Sleep Survey
por: Gamble, Amanda L., et al.
Publicado: (2014)

A prospective open‐label trial of a CBD/THC cannabis oil in dravet syndrome
por: McCoy, Bláthnaid, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_m3q8nbkt9853j7mvrpkb4dralk